Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research

Author(s): Stanislaw P. Stawicki, Thomas J. Papadimos

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 14 , 2013

Become EABM
Become Reviewer


Amniotic fluid embolism (AFE) continues to pose a formidable clinical challenge with its high rate of morbidity and mortality. A novel biomarker that acts as an early warning system for the clinician would be a welcomed addition to our medical armamentarium. Here we review the state of diagnosing AFE with our current methods of evaluation and testing along with recently discovered potential biomarkers that may be clinically efficacious. Additionally we explore the future of proteomics, lipidomics, and transcriptomics as tools to identify potential novel signaling pathways and biomarkers.

Keywords: Amniotic fluid embolism, biomarkers, diagnosis, management, proteomics, transcriptomics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1168 - 1178]
Pages: 11
DOI: 10.2174/1389201015666140430163921
Price: $65

Article Metrics

PDF: 39